The drug is pitolisant, sold under the brand name Wakix, and it represents a genuine departure from how medicine has traditionally treated excessive daytime sleepiness. Approved by the FDA in August 2019 for adults with narcolepsy, pitolisant works by blocking histamine 3 receptors in the brain, which increases natural histamine activity to promote wakefulness. Unlike every other wake-promoting medication on the market, it is not a controlled substance — not Schedule II, not Schedule IV, not scheduled at all. For the roughly 200,000 Americans living with narcolepsy, fewer than half of whom have been properly diagnosed, that distinction matters enormously. It means no DEA prescribing restrictions, no refill limitations, and a fundamentally different risk profile when it comes to dependence.
But pitolisant is not the only option worth understanding, and the landscape of non-stimulant treatments for excessive daytime sleepiness has grown considerably in recent years. Solriamfetol (Sunosi), modafinil, armodafinil, and oxybate-based therapies like Xywav and Lumryz each take a different pharmacological route to the same destination: helping people stay awake during the day without relying on traditional stimulants like amphetamines or methylphenidate. For families navigating dementia care, where sleep-wake cycle disruptions are common and stimulant side effects can be particularly dangerous, knowing these alternatives exist is not academic — it is practical. This article walks through how pitolisant works at the receptor level, how it compares to other non-stimulant options in terms of cost and scheduling, what the real-world limitations are, and what new treatments are approaching the market in 2026. If you or someone you care for struggles with excessive daytime sleepiness, this is the current state of what is available and what is coming.
Table of Contents
- How Does Pitolisant Treat Excessive Daytime Sleepiness Without Stimulants?
- Non-Stimulant Does Not Always Mean Unscheduled — Understanding the Other Options
- Oxybate-Based Treatments and the Once-Nightly Revolution
- Comparing Costs — What These Treatments Actually Cost Patients
- Why Excessive Daytime Sleepiness Is Underdiagnosed and Undertreated
- Solriamfetol’s Expanding Role Beyond Narcolepsy
- What the Next Year Could Bring for Non-Stimulant Sleep Treatments
- Conclusion
- Frequently Asked Questions
How Does Pitolisant Treat Excessive Daytime Sleepiness Without Stimulants?
Pitolisant works through a mechanism that has nothing in common with amphetamines, methylphenidate, or even the older wake-promoting agents like modafinil. It is a selective histamine 3 receptor antagonist and inverse agonist — which, in plain terms, means it blocks autoreceptors that normally tell the brain to stop releasing histamine. With those brakes removed, histamine neurons fire more actively, and histamine is one of the brain’s key wakefulness signals. Anyone who has taken an antihistamine like diphenhydramine and felt drowsy has experienced the flip side of this same system. Pitolisant essentially does the opposite: it amplifies the histamine signal rather than suppressing it. The dosing starts low at 8.9 mg once daily and can be titrated up to a maximum of 35.6 mg per day, giving physicians room to adjust based on individual response. Harmony Biosciences, the manufacturer, has steadily expanded its approved indications since that initial 2019 approval.
In October 2020, the FDA approved pitolisant for cataplexy in adults with narcolepsy. By June 2024, it gained approval for excessive daytime sleepiness in children aged six and older, and in February 2026, it received approval for cataplexy in that same pediatric population. That trajectory reflects growing confidence in the drug’s safety and efficacy profile across age groups. What makes pitolisant particularly relevant for older adults and those in dementia care settings is the controlled substance question. Traditional stimulants carry inherent risks of cardiovascular strain, agitation, and dependence — all of which become more concerning in aging populations or in patients with cognitive impairment. Pitolisant sidesteps those concerns entirely. It is the only wake-promoting agent that the DEA does not schedule, which means fewer barriers between the prescription pad and the pharmacy counter.
Non-Stimulant Does Not Always Mean Unscheduled — Understanding the Other Options
The phrase “non-stimulant” gets used loosely in sleep medicine, and it is worth being precise about what it does and does not mean. Solriamfetol (Sunosi), for instance, is classified as a wake-promoting agent rather than a stimulant, but it is still a Schedule IV controlled substance. It works as a dual dopamine and norepinephrine reuptake inhibitor, which is pharmacologically distinct from amphetamines but still involves neurotransmitter systems associated with abuse potential. For adults with narcolepsy or obstructive sleep apnea, solriamfetol is FDA-approved at doses of 75 mg or 150 mg once daily, and its efficacy is well-documented. However, if a patient or caregiver is specifically seeking something with zero scheduling and minimal abuse concern, solriamfetol does not quite meet that bar the way pitolisant does. Modafinil and its R-isomer armodafinil occupy a similar middle ground. They have been workhorses in sleep medicine for decades, and their generic availability makes them far more affordable than newer branded options.
But they too are Schedule IV controlled substances. Their mechanism of action remains somewhat poorly characterized — they are pharmacologically distinct from CNS stimulants, but they do affect dopamine reuptake to some degree. For many patients, modafinil or armodafinil will be the first treatment a physician reaches for, largely because of cost and familiarity. That is a perfectly reasonable starting point, but patients should understand that “non-amphetamine” and “non-controlled” are not the same thing. The distinction matters most when you are managing medications for someone with cognitive decline. Schedule IV drugs still require monitoring, can still interact with other medications common in dementia care, and still carry — however modest — some risk of misuse. For caregivers already juggling multiple prescriptions, the regulatory simplicity of a non-scheduled medication like pitolisant can reduce one more source of friction in an already complicated daily routine.
Oxybate-Based Treatments and the Once-Nightly Revolution
On the other end of the pharmacological spectrum sit the oxybate-based therapies, which treat both excessive daytime sleepiness and cataplexy by working on nighttime sleep architecture rather than daytime wakefulness directly. Xywav (a combination of calcium, magnesium, potassium, and sodium oxybates) is FDA-approved for patients aged seven and older with narcolepsy and represents a lower-sodium reformulation of the older drug Xyrem. These medications are taken at night and improve the quality and structure of sleep so profoundly that patients experience less daytime sleepiness as a consequence. The logic is counterintuitive — treat the night to fix the day — but the clinical evidence supports it. The practical drawback of oxybate therapy has historically been the dosing regimen. Xyrem and Xywav both required patients to wake up in the middle of the night to take a second dose, which is burdensome for anyone and particularly difficult for patients with cognitive impairment or their caregivers.
Lumryz, approved in 2023, solved this problem with a once-nightly extended-release formulation that eliminates the need for that middle-of-the-night awakening. For a caregiver managing a loved one’s narcolepsy alongside dementia symptoms, the difference between one nightly dose and a mandatory 2:00 a.m. alarm is not trivial. Looking ahead, Tris Pharma’s TRN-257 may further refine this category. The FDA accepted the new drug application on December 9, 2025, with a decision date set for June 20, 2026. TRN-257 would be the lowest-sodium once-nightly oxybate on the market — just 80 mg of sodium for a 9-gram dose — using proprietary RaftWorks and LiquiXR technology. It is seeking approval for cataplexy or excessive daytime sleepiness in adults with narcolepsy, as well as excessive daytime sleepiness in adults with idiopathic hypersomnia, a condition that currently has very few approved treatments.
Comparing Costs — What These Treatments Actually Cost Patients
Cost is often the deciding factor in which medication a patient actually ends up taking, regardless of what the clinical data suggests is optimal. Pitolisant is expensive by any measure: approximately $8,721 for a 30-day supply of 17.8 mg tablets, and even the lower 4.45 mg strength runs about $4,364 for 30 tablets. There is no generic available, and the drug is dispensed only through specialty pharmacies, which adds another layer of logistical complexity. For patients on Medicare or fixed incomes — a demographic that overlaps heavily with those in dementia care — these prices can be prohibitive even with insurance. Solriamfetol is less expensive but still substantial, with an average retail price around $1,231 for 30 tablets of the 150 mg strength.
Discount programs and coupons can bring that down to roughly $808 to $964, and Axsome Therapeutics offers a free 30-day trial voucher, which at least allows patients to assess whether the drug works before committing financially. No generic version of solriamfetol is expected until 2042, so price relief is not on the near horizon. The most affordable options in this category remain modafinil and armodafinil, which have been available as generics for years and typically cost a fraction of the branded alternatives. A 30-day supply of generic modafinil can often be obtained for under $50 with a coupon. The tradeoff is that modafinil and armodafinil are Schedule IV controlled substances and may not be appropriate for every patient. But when cost is the primary barrier to treatment — and for many families managing long-term care expenses, it absolutely is — generics remain the pragmatic choice.
Why Excessive Daytime Sleepiness Is Underdiagnosed and Undertreated
The statistics on narcolepsy diagnosis are sobering. Of the approximately 200,000 Americans affected, fewer than 50,000 have received a proper diagnosis — meaning roughly half of all people with narcolepsy are living without an explanation for their symptoms. Worldwide, an estimated 3 million people have the condition. The prevalence rate across North America, Europe, and South Korea combined is approximately 42.4 per 100,000 persons, and broader excessive daytime sleepiness affects between 0.9% and 9.1% of the general population depending on which symptoms are assessed and how strictly the criteria are applied. The diagnostic gap exists for several reasons, but one of the most relevant to dementia care is symptom overlap.
Excessive daytime sleepiness in an older adult is frequently attributed to aging, depression, medication side effects, or the dementia itself — and in many cases, those factors do contribute. But narcolepsy and idiopathic hypersomnia can coexist with or be masked by neurodegenerative conditions, and when clinicians default to the most obvious explanation, treatable causes get missed. A patient whose daytime sleepiness is dismissed as “just part of getting older” may go years without a sleep study that could change their quality of life. The warning here is straightforward: if someone in your care experiences excessive daytime sleepiness that does not improve with better sleep hygiene, medication adjustments, or treatment of depression, push for a formal sleep evaluation. The consequences of untreated excessive daytime sleepiness extend beyond drowsiness — they include increased fall risk, faster cognitive decline, social withdrawal, and caregiver burnout from constant supervision during waking hours.
Solriamfetol’s Expanding Role Beyond Narcolepsy
One of the more interesting developments in this space is solriamfetol’s potential expansion into conditions far beyond sleep disorders. The drug recently achieved its primary endpoint in the Phase III FOCUS trial for ADHD in adults, which could eventually give it a second major indication. It is also being studied for major depressive disorder, binge eating disorder, and shift work disorder.
For a medication originally approved for narcolepsy and obstructive sleep apnea, that pipeline suggests a broader mechanism of action with clinical relevance across multiple domains of brain function. This matters for the dementia care community because ADHD-like attention deficits and depressive symptoms frequently co-occur with cognitive decline. If solriamfetol proves effective across these indications, it could eventually become a single medication addressing several overlapping symptoms in older adults — wakefulness, attention, and mood — without the cardiovascular and psychiatric risks that come with traditional stimulants. That is speculative at this point, but the clinical trial data is heading in a promising direction.
What the Next Year Could Bring for Non-Stimulant Sleep Treatments
The June 20, 2026, PDUFA date for TRN-257 is the most concrete near-term event on the calendar. If approved, it would give patients and clinicians another once-nightly oxybate option with the lowest sodium content available — a meaningful differentiator for patients with hypertension or cardiovascular risk factors, which are common in the older populations most affected by both narcolepsy and dementia. The idiopathic hypersomnia indication, if granted, would also address a population that currently has almost no FDA-approved options.
More broadly, the trend in sleep medicine is moving clearly away from stimulant-first approaches and toward treatments that work with the brain’s natural wakefulness and sleep systems. Pitolisant’s histamine pathway, solriamfetol’s dopamine and norepinephrine reuptake inhibition, and the oxybates’ sleep architecture remodeling each represent a fundamentally different philosophy from simply forcing the brain into an alert state with amphetamines. For patients with fragile neurological conditions — including dementia — that shift in philosophy is not just welcome, it is necessary.
Conclusion
The treatment of excessive daytime sleepiness has changed substantially in the past seven years, and patients now have real alternatives to stimulants. Pitolisant stands alone as the only completely unscheduled wake-promoting agent, making it a particularly compelling option for patients in dementia care where controlled substance management is already complex. Solriamfetol, modafinil, armodafinil, and the oxybate-based therapies each offer distinct mechanisms and tradeoffs in terms of efficacy, scheduling, cost, and convenience.
The right choice depends on the individual — their diagnosis, their other medications, their insurance coverage, and their tolerance for the logistics of specialty pharmacy dispensing. If you are a caregiver or family member managing excessive daytime sleepiness in someone with cognitive decline, the single most important step is getting a proper sleep evaluation rather than assuming the sleepiness is inevitable. Once a diagnosis is established, the conversation with a sleep specialist should include all of the non-stimulant options discussed here, with honest discussion about cost, access, and what each medication can and cannot do. The landscape is better than it was a decade ago, and with TRN-257 potentially arriving later this year, it continues to improve.
Frequently Asked Questions
Is pitolisant (Wakix) safe for older adults with dementia?
Pitolisant has been studied primarily in narcolepsy patients, and there are no large-scale trials specifically in dementia populations. However, its non-controlled status and histamine-based mechanism make it pharmacologically less risky than stimulants for older adults. Any use in patients with dementia should be discussed with both a sleep specialist and the patient’s neurologist.
Can these medications be used for sleepiness caused by dementia itself rather than narcolepsy?
Most of these drugs are FDA-approved specifically for narcolepsy or obstructive sleep apnea, not for sleepiness associated with neurodegenerative disease. Off-label use is possible but should be guided by a physician who understands both conditions. The underlying cause of the sleepiness matters for choosing the right treatment.
Why is pitolisant so expensive if it is not even a controlled substance?
Pitolisant is a branded medication with no generic alternative, manufactured by a single company (Harmony Biosciences) and dispensed exclusively through specialty pharmacies. The lack of generic competition and the relatively small patient population with narcolepsy both contribute to the high price. Patient assistance programs may be available through the manufacturer.
What is the difference between Xywav and Lumryz?
Both are oxybate-based medications approved for narcolepsy. Xywav is a low-sodium formulation that requires two doses per night — one at bedtime and one taken several hours later. Lumryz is an extended-release formulation approved in 2023 that only requires a single dose at bedtime, eliminating the disruptive middle-of-the-night second dose.
How do I know if excessive daytime sleepiness needs medical evaluation versus just better sleep habits?
If sleepiness persists despite consistently getting seven or more hours of sleep at night, does not improve with better sleep hygiene, and interferes with daily functioning or safety, it warrants a medical evaluation. A sleep study (polysomnography followed by a multiple sleep latency test) is the standard diagnostic approach for conditions like narcolepsy and idiopathic hypersomnia.
